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Leprosy as Immune 
Reconstitution 
Inﬂ  ammatory 
Syndrome in HIV-
positive Persons
To the Editor: More than 2 de-
cades ago, when HIV was ﬁ  rst  de-
tected, many investigators predicted 
the rise of leprosy secondary to op-
portunistic infection (1). Recently, the 
phenomenon of immune reconstitu-
tion inﬂ   ammatory syndrome (IRIS), 
or leprosy reversal response, has re-
ceived attention. IRIS often occurs 
secondary to initiating highly active 
antiretroviral therapy (HAART). The 
ﬁ  rst indications of an interaction be-
tween HIV and Mycobacterium leprae 
occurred only recently, with the iden-
tiﬁ   cation of IRIS after initiation of 
HAART in patients with HIV and pre-
viously undetected leprosy. A review 
by Pustianowski et al. discusses the 
paradox of HIV and leprosy with IRIS 
(2). In addition, Lawn et al. described 
the ﬁ  rst case of IRIS after the onset of 
HAART in a patient who had tubercu-
loid leprosy that was never conﬁ  rmed 
by molecular analysis (3). 
Multiple reports (4–7) unmasked 
subclinical Hansen disease (M. lep-
rae infection) occurring with HAART 
or spontaneously (8). In case reports 
by Lu et al. (6) and Sharma et al. (7), 
leprosy was associated with erythema 
nodosum leprosum. Pereira et al. dis-
covered that patients known to have 
HIV and leprosy, when treated with 
HAART manifested a type 1 reversal 
reaction, acute leprosy inﬂ  ammatory 
episode (4), or IRIS. We describe the 
ﬁ  rst, to our knowledge, 2 cases in the 
United States of HIV and leprosy in-
fections in which IRIS has occurred 
after HAART initiation and which has 
been conﬁ  rmed by molecular analysis.
Three skin-biopsy samples, 2 
from patient 1 and 1 from patient 2, 
were analyzed to conﬁ  rm the presence 
of M. leprae. Patient 1 met the diag-
nostic criteria for leprosy according 
to biopsy result; patient 2’s case was 
compatible  with such criteria. Each 
patient was treated for leprosy, and 
each responded favorably. The pur-
pose of our case study was to conﬁ  rm 
M. leprae DNA in skin samples. The 
skin specimens were parafﬁ  n-embed-
ded slides. DNA was extracted by 
standard molecular biologic methods 
that used xylene. PCR ampliﬁ  ed the 
M. leprae heat shock protein 65 gene 
(hsp65). After ampliﬁ  cation,  restric-
tion fragment-length polymorphism 
(RFLP)–polyacrylamide gel electro-
phoresis (PAGE) was performed with 
HaeIII (6).
Patient 1 was a 60-year-old His-
panic man who was ﬁ  rst evaluated in 
Los Angeles, California, with skin le-
sions covering >50% of his body. He 
reported having erythematous scaly 
plaques that had been waxing and 
waning for several months. Several 
skin biopsy samples were taken, and 
an HIV test was conducted; results 
showed that he had lepromatous lep-
rosy and was HIV positive. Biopsy 
specimens were both Fite stain posi-
tive for numerous acid-fast bacilli. 
Three months after HAART was initi-
ated, repeat skin biopsy samples were 
taken from nodules that had recently 
developed on his right arm and torso. 
Histologic assessment showed Fite 
stain–positive granulomatous derma-
titis with many foamy cells. He was 
treated for leprosy and is continuing 
HAART.
Patient 2 was a 37-year-old West 
African black man from Burkina Faso 
who was evaluated in New York for 
gram-negative bacteremia. He was 
admitted and treated for disseminat-
ed salmonellosis and was found to 
be HIV positive. His T-lymphocyte 
count was 7/μL. He was promptly 
prescribed HAART and responded 
well to treatment: his T-cell count 
rose to 112/μL during 5 months and 
is currently >700/μL. Within 2 years 
of HAART initiation, multiple anes-
thetic, hypopigmented skin macules 
that failed to resolve over 6 months 
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developed. These macules developed 
further into nodules. Punch biopsy re-
sults were consistent with granuloma-
tous dermatitis. Fite stain was negative 
for acid-fast bacilli, but leprosy was 
diagnosed on the basis of anesthesia 
localized to his skin lesions. When the 
biopsy samples were taken, the patient 
was receiving dapsone in addition 
to HAART. Rifampin treatment was 
started subsequent to biopsies.
PCR ampliﬁ  cation for M. leprae 
hsp65 was positive for all 3 samples. 
Thus, mycobacterial DNA was pres-
ent in both patients. The RFLP analy-
sis results are shown in the Figure. 
The  hsp65 RFLP pattern for patient 
1 was identical to those described by 
Martiniuk et al. (9) and for the wild-
type pattern for patient 2, as shown by 
Lu et al. (6), thus demonstrating the 
presence of M. leprae DNA in these 
samples.
Previous studies have highlight-
ed the low rate of HIV and leprosy 
co-infection. For example in Ethio-
pia, Frommel et al. noted that, before 
HAART was available in resource-
poor settings, increased HIV seroposi-
tivity did not alter the natural course 
of leprosy nor increase the number of 
patients with M. leprae (10). Never-
theless, positive reports of IRIS and 
leprosy after initiation of HAART 
have been reported from other nations 
(3–5). If this syndrome can be detect-
ed even in the mildly leprosy–endemic 
United States (8), an increase in simi-
lar cases in areas where HIV and lep-
rosy occur in higher frequency can be 
anticipated.
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Endocarditis 
after Use of 
Tongue Scraper
To the Editor: Tongue scraping 
is advocated as a therapy for manag-
ing halitosis and as a technique for 
preventing dental caries by reduc-
ing bacterial counts in the mouth (1). 
The practice has been in existence for 
centuries (2). A Cochrane review has 
concluded that tongue cleaning is mar-
ginally and temporarily more effective 
than use of a toothbrush in reducing 
a measurable marker for halitosis, ex-
haled volatile sulfur compounds (3). 
The use of tongue scrapers may not be 
limited to those with clinical halitosis, 
as 10%–30% of Americans report bad 
breath (4), and websites offer to solve 
the problem of “your bad breath” for a 
price. We report the case of a woman 
in whom infective endocarditis fol-
lowed the use of a tongue scraper.
A 59-year-old woman with a 
known history of mitral valve prolapse 
with associated valvular regurgitation 
had onset of progressive malaise, fe-
ver, sweats, myalgia, and headache; the 
symptoms lasted 10 days. Two months 
previously she had begun cleaning her 
tongue with a plastic tongue scraper 
purchased at her local pharmacy. She 
had not undergone recent dental work. 
Her medical background included mi-
graines, hypertension, mild quiescent 
psoriasis, and previous depression. 
Her medications were venlafaxine and 
candesartan.
When seen at her local hospital, 
she reported severe headache and 
myalgia, with fever. The same day, 
she had a rigor at home and reported 
chest tightness and mild dyspnea. 
Physical examination showed no fo-
cal ﬁ  ndings other than the mitral valve 
prolapse. A provisional diagnosis of 
bacterial meningitis was made. Emer-
gency treatment comprised intrave-
nous dexamethasone, ceftriaxone, 
and benzylpenicillin. Cerebrospinal 
ﬂ  uid analysis performed shortly after 
showed no cells and normal glucose 
and protein levels. Culture of the cere-
brospinal ﬂ  uid was negative. No fur-
ther antimicrobial agents were admin-
istered. Multiple blood cultures were 
drawn but remained culture negative. 
Serologic tests for Q fever, Bartonella 
spp., and endemic rickettsiae were 
negative. She continued to be febrile.
A transthoracic echocardiogram 
showed dilatation of the mitral valve 
annulus with bi-leaﬂ   et prolapse and 
vegetation attached to the anterolat-
eral commissure. She was referred to 
a tertiary care center, and therapy with 
penicillin,  ﬂ   ucloxacillin, and genta-
micin was begun for culture-negative 
endocarditis. Transesophageal echo-
cardiography and visual examination 
at the time of valve replacement con-
ﬁ  rmed the presence of large valvular 
vegetations. After infected tissue was 
excised, a prosthetic mitral valve was 
placed. Extended culturing of the 
blood failed to identify a pathogen. 
Histopathologic examination of the 
explanted valve identiﬁ  ed  ﬁ  brinopu-
rulent vegetations with destruction of 
the valve leaﬂ  et. The excised material 
was split into sections and submitted 
for culture; all demonstrated a scant 
growth of Haemophilus parainﬂ  u-
enzae. This ﬁ  nding was identiﬁ  ed by 
a Remel RapID NH Panel (Remel, 
Lenexa, KS, USA) and conﬁ  rmed by 
16S rRNA gene sequencing. The pa-
tient was treated with ampicillin and 
gentamicin for 2 weeks. She then had 
4 further weeks of therapy with daily 
ceftriaxone at home. She is now well.
This patient’s endocarditis was 
most likely caused by bacteremia 
from tongue scraping, and the ab-
normal valve is likely to have been a 
predisposing factor. The link between 
oral  ﬂ   ora and endocarditis has long 
been recognized (5), and guidelines 
for prophylactic use of antimicrobial 
agents before dental manipulation are 
established. A literature review did not 
show any previous reports of endocar-
titis associated with use of a tongue 
scraper. There are numerous reports 
of endocarditis after tongue piercing, 
with a variety of organisms including 
viridans streptococci, H. aphrophi-
lus, Neisseria mucosa, and methicil-
lin-resistant  Staphylococcus aureus 
(6–9). Most of these articles reported 
a pre-existing valvular abnormality, 
as in our case. Bacteremia caused by 
routine tooth brushing does not ap-
pear to be clinically important, and 
there are conﬂ  icting data about its fre-
quency (10). The inoculum of bacteria 
transmitted into the bloodstream with 
brushing may be smaller than that with 
tooth extraction. Given the frequency 
of routine tooth brushing, antimicro-
bial prophylaxis is impractical in any 
case. The practice of tongue scraping, 
however, has not been well studied, 
and both the magnitude and frequen-
cy of bacteremia may be greater than 
with routine tooth brushing.
We propose that our patient’s in-
fective endocarditis was most likely a 
consequence of bacteremia from her 
use of a tongue scraper. Persons with 
abnormal cardiac valves and intra-
vascular devices such as pacemakers 
may be at particular risk. Patients with 
previous infective endocarditis and 
high-risk cardiac valve defects should 
be informed that tongue scraper use is 
not prudent.